26 Jul ExCellThera
David Millette, CEO
Oct. 7 | 2:45pm | FLW Ballroom F
Montreal, Canada
(Private)
ExCellThera is world leader in enhanced blood stem cell expansion and therapies. Its most advanced product UM171 Cell Therapy (INN-dorocubicel), is in late stages of development. A Market Authorization Application for UM171 Cell Therapy has been accepted for an accelerated assessment by EMA for the treatment of patients with hematological malignancies requiring an HSCT who lack a suitable donor. Following a favorable EOP2 meeting with FDA, a Phase-3 trial is planned in high and very-high risk acute leukemias and myelodysplasias for which limited treatment options exist with low survival and high incidence of relapse under standard of care. UM171 Cell Therapy in other indications, including pediatric patients, mutliple myeloma, and non-malignant hematological diseases, is also explored. ExCellThera partners with biopharmas to them help develop best-in-class cell and gene therapies by leveraging proprietary molecule UM171 which has first-in-class mechanism of action for ex-vivo expansion and metabolic fitness of HSCs.